NCT06444880 2026-01-08Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient MalignanciesM.D. Anderson Cancer CenterPhase 2 Recruiting40 enrolled